Srinath Thirumalai rajan

Srinath Thirumalairajan, is Executive Director of CMC at Callio Therapeutics, where he provides leadership across CMC strategy for complex bioconjugate and small molecule programs. A trained synthetic organic and medicinal chemist, Srinath brings extensive experience in cGMP development, process engineering, and manufacturing for advanced therapeutic modalities. Prior to Callio Therapeutics, he held senior CMC and process engineering leadership roles at Pfizer, Seagen, Abzena, and NJ Bio, supporting late stage development and GMP manufacturing of bioconjugates and ADCs.